Urology reports (St. - Petersburg)Urology reports (St. - Petersburg)2225-90742687-1416Eco-Vector1633010.17816/uroved9459-72Research ArticleSignificance of the pharmacoeconomic approach in the choice of treatment of hyperplasia of the prostatePeshekhonovKirill S.<p>Postgraduate, Urology Department</p>ispesh@gmail.comShpileniaEvgeniy S.<p>Doctor of Medical Science, Professor, Urology Department</p>spilenya@mail.ruBurlakaOleg O.<p>Candidate of Medical Science, Head of Department of Urology</p>burlaka@list.ruNorth-Western State Medical University named after I.I. MechnikovAleksandrovskaya Hospital291220199459720510201924112019Copyright © 2020, Peshekhonov K.S., Shpilenia E.S., Burlaka O.O.2020<p>The article presents an analysis of literature data on the study of the medical and economic aspects of medical, surgical and minimally invasive methods of treating patients with the lower urinary tract symptoms due to prostatic hyperplasia. It was noted that modern surgical treatment, new minimally invasive technologies have certain clinical and economic advantages in the long term compared with drug therapy in carefully selected patients with prostatic hyperplasia.</p>prostate glandbenign prostatic hyperplasialower urinary tract symptomspharmacoeconomic analysisendoscopic urologyпредстательная железадоброкачественная гиперплазия предстательной железысимптомы нижних мочевых путейфармакоэкономический анализэндоскопическая урология[European Association of Urology. Gravas S, Cornu JN, Gacci M, et al. Management of non-neurogenic male LUTS. EAU; 2019. Available from: https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts.][Сорокин Н.И., Дымов А.М., Суханов Р.Б., и др. Результаты лечения больных доброкачественной гиперплазией предстательной железы с помощью гольмиевой лазерной энуклеации (HoLEP) на этапе освоения методики // Медицинский вестник Башкортостана. – 2015. – Т. 10. – № 3. – С. 238–240. [Sorokin NI, Dymov AM, Sukhanov RB, et al. The results of treatment of patients with benign prostate hyperplasia using holmium laser enucleation (hоlep) at the stage of development of a technique. Bashkortostan medical journal. 2015;10(3):238-240. (In Russ.)]][Урология. Российские клинические рекомендации / Под ред. Ю.Г. Аляева, П.В. Глыбочко, Д.Ю. Пушкаря. – М.: Медфорум, 2017. – 544 с. [Urologiya. Rossiyskiye klinicheskiye rekomendatsii. Ed. by Yu.G. Alyaev, P.V. Glybochko, D.Yu. Pushkar’. Moscow: Medforum; 2017. 544 р. (In Russ.)]][Шпиленя Е.С. Экономика должна быть экономной // Дайджест урологии [интернет-ресурс]. – 2017. – № 3–4. – C. 2–16. [Shpilenya ES. Ekonomika dolzhna byt’ ekonomnoy. Daydzhest urologii [internet-resurs]. 2017;(3-4):2-16. (In Russ.)]. Доступно по: http://urodigest.ru/sites/default/files/issue/03-04-2017.pdf. Ссылка активна на 15.08.2019.][Hollingsworth JM, Wei JT. Economic impact of surgical intervention in the treatment of benign prostatic hyperplasia. Rev Urol. 2006;8(Suppl. 3):9-15.][Наумов А.В., Алексеев И.Д., Будылев С.А., и др. Болезни стареющих мужчин: в фокусе предстательная железа // Врач скорой помощи. – 2011. – № 6. – С. 31–39. [Naumov AV, Alekseev ID, Budylev SA, et al. Diseases of aging men: prostate in focus. Vrach skoroy pomoshchi. 2011;(6):31-39. (In Russ.)]][Просянников М.Ю. Результаты внедрения комплексной этапной стандартизированной программы диагностики и лечения доброкачественной гиперплазии предстательной железы // Социальные аспекты здоровья населения. – 2014. – № 6. – С. 7–11. [Prosyannikov MYu. Implementation results of the comprehensive standardized step-wise program on benign prostatic hyperplasia diagnosis and treatment. Social aspects of population health. 2014;(6):7-11. (In Russ.)]][Lepor H. The evolution of alpha-blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2006;8(Suppl. 4):3-9.][Amerson D. Urolift for BPH: changing the game in BPH care, presentation at AACU state advocacy conference, Sept 18-19. Chicago; 2015.][Vuichoud C, Loughlin K. Benign prostatic hyperplasia: epidemiology, economics, and evaluation. Can J Urol. 2015;22(Suppl. 1):1-6.][Fowke JH, Munro H, Signorello LB, et al. Association between socioeconomic status (SES) and lower urinary tract symptom (LUTS) severity among black and white men. J Gen Intern Med. 2011;26(11):1305-1310. https://doi.org/10.1007/s11606-011-1776-8.][Лопаткин Н.А., Сивков А.В., Зиборова И.В. Социально-экономические аспекты федеральной целевой программы «Урология» // Экономика здравоохранения. – 1999. – № 4–3. – С. 12–15. [Lopatkin NA, Sivkov AV, Ziborova IV. Sotsial’no-ekonomicheskiye aspekty federal’noy tselevoy programmy “Urologiya”. Ekonomika zdravookhraneniya. 1999;(4-3):12-15. (In Russ.)]][Просянников М.Ю., Цой А.А., Мадыкин Ю.Ю. Организация трехуровневой системы медицинской помощи в урологии. – М.: Уромедиа, 2017. – 122 с. [Prosyannikov MYu, Tsoy AA, Madykin YuYu. Organizatsiya trekhurovnevoy sistemy meditsinskoy pomoshchi v urologii. Moscow: Uromedia; 2017. 122 р. (In Russ.)]][Gravas S, Oelke M. Current status of 5α-reductase inhibitors in the management of lower urinary tract symptoms and BPH. World J Urol. 2010;28(1):9-15. https://doi.org/10.1007/s00345-009-0493-y.][Glynn RJ, Campion EW, Bouchard GR, Silbert JE. The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol. 1985;121(1):78-90. https://doi.org/10.1093/oxfordjournals.aje.a113986.][Крысанов И.С. Введение в фармакоэкономическое моделирование // Фармакоэкономика. – 2008. – Т. 1. – № 1. – С. 7–9. [Krysanov IS. Introduction into pharmacoeconomic modelling. Farmakoekonomika. 2008;1(1):7-9. (In Russ.)]][Caine M, Pfau A, Perlbert S. The use of alpha adrenergic blockers in benign prostatic obstruction. Br J Urol. 1976;48(3):255-263. https://doi.org/10.1111/j.1464-410x.1976.tb10214.x.][ProState of the nation report: a call to action: delivering more effective care for BPH patients in the UK. GlaxoSmithKline, Brentford, UK; 2009.][Jepsen JV, Bruskewitz RC. Recent developments in the surgical management of benign prostatic hyperplasia. Urology. 1998;51(Suppl. 4):23-31. https://doi.org/10.1016/s0090-4295(98) 00052-1.][Lanes SF, Sulsky S, Walker AM, et al. A cost density analysis of benign prostatic hyperplasia. Clin Ther. 1996;18(5):993-1004. https://doi.org/10.1016/s0149-2918(96)80055-5.][NDC Health Pharmaceutical Audit Site Prescription Monthly, authors. The top 200 prescriptions for 2004 by U.S. Sales ($ billions) [cited 2006 August 19]. Available from: http://www.rxlist.com/top200_sales_2004.htm.][Treharne C, Crowe L, Booth D, Ihara Z. Economic value of the transurethral resection in saline system for treatment of benign prostatic hyperplasia in England and Wales: systematic review, meta-analysis, and cost-consequence model. Eur Urol Focus. 2018;4(2):270-279. https://doi.org/10.1016/j.euf.2016.03.002.][McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 1998;338(9):557-563. https://doi.org/10.1056/nejm199802263380901.][Nunes RL, Antunes AA, Constantin DS. Contemporary surgical treatment of benign prostatic hyperplasia. Rev Assoc Med Bras. 2017;63(8):711-716. https://doi.org/10.1590/1806-9282.63. 08.711.][Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123-131. https://doi.org/10.1016/j.eururo.2009.09.035.][Naslund MJ, Issa MM, Grogg AL, et al. Clinical and economic outcomes in patients treated for enlarged prostate. Am J Manag Care. 2006;12(Suppl. 4):S111-116.][Messina R, Mirone V. Benign prostatic hyperplasia – an economic assessment of fixed combination therapy based on a literature review. Arch Ital Urol Androl. 2015;87(3):185-189. https://doi.org/10.4081/aiua.2015.3.185.][Naslund M, Eaddy MT, Kruep EJ, et al. Cost comparison of finasteride and dutasteride for enlarged prostate in a managed care setting among medicare-aged men. Am J Manag Care. 2008;14(5 Suрpl. 2):S167-171.][DerSarkissian M, Xiao Y, Duh MS, et al. Comparing clinical and economic outcomes associated with early initiation of combination therapy of an alpha blocker and dutasteride or finasteride in men with Benign Prostatic Hyperplasia in the United States. J Manag Care Spec Pharm. 2016;22(10):1204-1214. https://doi.org/10.18553/jmcp.2016.22.10.1204.][Elterman DS, Barkin J, Kaplan SA. Optimizing the management of benign prostatic hyperplasia. Ther Adv Urol. 2012;4(2):77-83. https://doi.org/10.1177/1756287212437361.][Кожанова И.Н., Романова И.С., Гавриленко Л.Н. Фармакоэкономическая оценка применения дутастерида и финастерида у пациентов с доброкачественной гиперплазией предстательной железы // Медицинские новости. – 2011. – № 8. – С. 47–54. [Kozhanova IN, Romanova IS, Gavrilenko LN. Farmakoekonomicheskaya otsenka primeneniya dutasterida i finasterida u patsiyentov s dobrokachestvennoy giperplaziyey predstatel’noy zhelezy. Meditsinskiye novosti. 2011;(8):47-54. (In Russ.)]][Поляков В.В. Фармакологические и клинико-экономические подходы к оптимизации комплексного лечения доброкачественной гиперплазии простаты: Автореф. дис. … канд. мед. наук. – Курск, 2008. – 22 с. [Polyakov VV. Farmakologicheskiye i kliniko-ekonomicheskiye podkhody k optimizatsii kompleksnogo lecheniya dobrokachestvennoy giperplazii prostaty. [dissertation abstract]. Kursk, 2008. 22 р. (In Russ.)]. Доступно по: https://www.dissercat.com/content/farmakologicheskie-i-kliniko-ekonomicheskie-podkhody-k-optimizatsii-kompleksnogo-lecheniya-d. Ссылка активна на 01.10.2019.][Fenter TC, Runken MC, Black L, Eaddy M. Finasteride versus dutasteride: a real-world economic evaluation. Am J Manag Care. 2007;13(Suppl 1): S23-28.][Мустафаев А.Т., Кызласов П.С., Дианов М.П., и др. Хирургическое лечение доброкачественной гиперплазии предстательной железы: прошлое и настоящее // Урологические ведомости. – 2019. – Т. 9. – № 1. – С. 47–56. [Mustafaev AT, Kyzlasov PS, Dianov MP, et al. Surgical treatment of benign prostatic hyperplasia: the past and the present. Urologicheskie vedomosti. 2019;9(1):47-56. (In Russ.)]. https://doi.org/10.17816/uroved9147-56.][Перепанова Т.С. Медикаментозная терапия доброкачественной гиперплазии предстательной железы с позиций доказательной медицины и фармакоэкономики // Consilium Medicum. – 2001. – Т. 3. – № 7. – C. 316–322. [Perepanova TS. Medikamentoznaya terapiya dobrokachestvennoy giperplazii predstatel’noy zhelezy s pozitsiy dokazatel’noy meditsiny i farmakoekonomiki. Consilium Medicum. 2001;3(7):316-322. (In Russ.)]][Fusco F, Arcaniolo D, Creta M, et al. Demographic and comorbidity profile of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a real-life clinical setting: are 5-alpha-reductase inhibitor consumers different? World J Urol. 2015;33(5):685-689. https://doi.org/10.1007/s00345-014-1460-9.][Park J, Lee YJ, Lee JW, et al. Comparative analysis of benign prostatic hyperplasia management by urologists and nonurologists: a Korean nationwide health insurance database study. Korean J Urol. 2015;56(3):233-239. https://doi.org/10.4111/kju.2015.56.3.233.][Лоран О.Б., Пушкарь Д.Ю., Раснер П.И. Сравнительная оценка эффективности и безопасности комбинированной терапии больных с доброкачественной гиперплазией простаты препаратами финастеридом и альфузозином // Урология. – 2002. – № 1. – С. 19–22. [Loran OB, Pushkar’ DYu, Rasner PI. Sravnitel’naya otsenka effektivnosti i bezopasnosti kombinirovannoy terapii bol’nykh s dobrokachestvennoy giperplaziyey prostaty preparatami finasteridom i al’fuzozinom. Urologiia. 2002;(1):19-22. (In Russ.)]][Athanasopoulos A, Perimenis P. Efficacy of the combination of an alpha 1-blocker with an anticholinergic agent in the treatment of lower urinary tract symptoms associated with bladder outlet obstruction. Expert Opin Pharmacother. 2005;6(14):2429-2433. https://doi.org/10.1517/14656566.6.14.2429.][Cindolo L, Pirozzi L, Sountoulides P, et al. Patient’s adherence on pharmacological therapy for benign prostatic hyperplasia (BPH) associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy? BMC Urol. 2015;15:96-102. https://doi.org/10.1186/s12894-015-0090-x.][Madersbacher S, Marszalek M, Lackner J, et al. The long-term outcome of medical therapy for BPH. Eur Urol. 2007;51(6): 1522-1533. https://doi.org/10.1016/j.eururo.2007.03.034.][Johnson NJ, Kirby R. Cost-effectiveness analysis of alpha blocker therapy for the treatment of benign prostatic hyperplasia. Eur Urol. 1996;30(Suppl. 2):152.][Верткин А.Л., Лоран О.Б., Вовк Е.И., и др. Доброкачественная гиперплазия предстательной железы и ее осложнения в общемедицинской практике // Consilium Medicum. – 2011. – № 4. – С. 16–19. [Vertkin AL, Loran OB, Vovk EI, et al. Dobrokachestvennaya giperplaziya predstatel’noy zhelezy i eye oslozhneniya v obshchemeditsinskoy praktike. Consilium Medicum. 2011;(4): 16-19. (In Russ.)]][Disantostefano RL, Biddle AK, Lavelle JP. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia. BJU Int. 2006;97(5):1007-1016. https://doi.org/10.1111/j.1464-410x.2005.06089.x.][Rossi C, Kortmann BB, Sonke GS, et al. Alpha-Blockade improves symptoms suggestive of bladder outlet obstruction_but fails to relieve it. J Urol. 2001;165(1):38-41. https://doi.org/10.1097/00005392-200101000-00010.][DiSantostefano RL, Biddle AK, Lavelle JP. The long-term cost effectiveness of treatments for benign prostatic hyperplasia. Pharmacoeconomics. 2006;24(2):171-191. https://doi.org/10.2165/00019053-200624020-00006.][Lowe FC, McDaniel RL, Chmiel JJ, Hillman AL. Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia. Urology. 1995;46(4):477-483. https://doi.org/10.1016/s0090-4295(99)80258-1.][Cockrum PC, Finder SF, Ries AJ, Potyk RP. A pharmacoeconomic analysis of patients with symptoms of benign prostatic hyperplasia. Pharmacoeconomics. 1997;11(6):550-565. https://doi.org/10.2165/00019053-199711060-00004.][Noble SM, Coast J, Brookes S, et al. Transurethral prostate resection, noncontact laser therapy or conservative management in men with symptoms of benign prostatic enlargement? An economic evaluation. J Urol. 2002;168(6):2476-2482. https://doi.org/10.1016/s0022-5347(05)64172-9.][McDonald H, Hux M, Brisson M, et al. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia. Can J Urol. 2004;11(4):2327-2340.][Ahn HS, Kim SJ, Choi JB, et al. Long-term cost comparison between surgical and medical therapy for benign prostatic hyperplasia: a study using hospital billing data. BJU Int. 2019. 123(5A):E79-85. https://doi.org/10.1111/bju.14584.][Шайдуллин Р.М., Ситдыков Э.Н., Зубков А.Ю., Ситдыкова М.Э. Клинико-экономическое обоснование преимуществ аденомэктомии в лечении аденомы предстательной железы // Практическая медицина. – 2013. – № 1–4. – С. 126–129. [Shaydullin RM, Sitdykov EN, Zubkov AYu, Sitdykova ME. Clinical and economic evaluation of adenomectomy advantages in the treatment of prostatic adenoma. Prakticheskaya medizina. 2013;(1-4):126-129. (In Russ.)]][Перепанова Т.С., Хазан П.Л., Солнцева Т.В. Фармакоэкономический анализ оперативного и медикаментозного лечения доброкачественной гиперплазии предстательной железы // Русский медицинский журнал. – 2005. – Т. 13. – № 9. – С. 623–628. [Perepanova TS, Hasan PL, Solnzeva TV. Farmakoekonomicheskiy analiz operativnogo i medikamentoznogo lecheniya dobrokachestvennoy giperplazii predstatel’noy zhelezy. Russkiy meditsinskiy zhurnal. 2005;13(9):623-628. (In Russ.)]][Овод А.И., Дремова Н.Б. Лекарственные аспекты лечения доброкачественной гиперплазии предстательной железы (рынок, стоимость, лекарственная терапия, мнения больных) // Ремедиум. Журнал о российском рынке лекарств и медицинской техники. – 2005. – № 4. – С. 36–41. [Ovod AI, Dremova NB. Lekarstvennyye aspekty lecheniya dobrokachestvennoy giperplazii predstatel’noy zhelezy (rynok, stoimost’, lekarstvennaya terapiya, mneniya bol’nykh). Remedium. Zhurnal o rossiyskom rynke lekarstv i meditsinskoy tekhniki. 2005;(4):36-41. (In Russ.)]][Кожанова И.Н., Романова И.С., Гавриленко Л.Н. Фармакоэкономическая оценка применения ингибиторов 5-альфа-редуктазы в условиях здравоохранения Республики Беларусь // Медицинские технологии. Оценка и выбор. – 2011. – № 3. – С. 22–29. [Kozhanova IN, Romanova IS, Gavrilenko LN Pharmacoeconomic evaluation of 5-alpha-reductase inhibitors in the Belarus healthcare system. Medical technologies. 2011;(3):22-29. (In Russ.)]][Lourenco T, Armstrong N, N’Dow J, et al. Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement. Health Technol Assess. 2008;12(35):1-168. https://doi.org/10.3310/hta12350.][Еникеев Д.В., Глыбочко П.В., Аляев Ю.Г., и др. Сравнительный анализ эффективности различных методик эндоскопической энуклеации простаты // Хирургия. Журнал им. Н.И. Пирогова. – 2017. – № 11. – С. 4–14. [Enikeev DV, Glybochko PV, Alyaev YuG, et al. Comparative analysis of the effectiveness of various techniques of endoscopic prostate enucleation in a single center. Khirurgiia. 2017;(11);4-14. (In Russ.)]. https://doi.org/10.17116/hirurgia2017114-14.][Gill BC, Ulchaker JC. Costs of managing benign prostatic hyperplasia in the office and operating room. Curr Urol Rep. 2018;19(9):72. https://doi.org/10.1007/s11934-018-0822-z.][Masucci L, Erman A, Krahn MD, Elterman D. Cost analysis of Greenlight photoselective vaporization of the prostate compared to transurethral resection of the prostate for benign prostatic hyperplasia. Can Urol Assoc J. 2018. https://doi.org/10.5489/cuaj.5267.][DeWitt-Foy ME, Gill BC, Ulchaker JC. Cost comparison of Benign Prostatic Hyperplasia treatment options. Curr Urol Rep. 2019;20(8):45. https://doi.org/10.1007/s11934-019-0907-3.][Jung JH, McCutcheon KA, Reddy B, et al. Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database Syst Rev. 2019;5: CD012832. https://doi.org/10.1002/14651858.CD012832.pub2.][Bagla S, Smirniotopoulos J, Orlando J, Piechowiak R. Cost Analysis of Prostate Artery Embolization (PAE) and Transurethral Resection of the Prostate (TURP) in the treatment of benign prostatic hyperplasia. Card Int Radiol. 2017;40(2):1694-1697. https://doi.org/10.1007/s00270-017-1700-7.][Mullhaupt G, Hechelhammer L, Engeler D, et al. In hospital cost analysis of prostatic artery embolization compared to transurethral resection of the prostate: post hoc analysis of a randomized controlled trial. BJU Int. 2019;123(6):1055-1060. https://doi.org/10.1111/bju.14660.][Ulchaker JC, Martinson MS. Cost-effectiveness analysis of six therapies for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Clin Outcomes Res. 2018;10:29-43. https://doi.org/10.2147/CEOR.S148195.][Cleveland Clinic. Comparing the costs of various treatments for benign prostatic hyperplasia. [cited 2019 March 11] Available from: https://consultqd.clevelandclinic.org/comparing-the-costs-of-various-treatments-for-benign-prostatic-hyperplasia.]